LOC100505715: A Drug Target / Disease Biomarker (G100505715)
LOC100505715: A Drug Target / Disease Biomarker
LOC100505715 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of leucine-rich repeat (LRR) proteins, which are characterized by the presence of a characteristic leucine-rich repeat in their amino acid sequence. LRR proteins are known for their ability to form aggregates, which can be both beneficial and detrimental depending on the context. In this article, we will discuss the potential implications of LOC100505715 as a drug target or biomarker.
The LRR protein that LOC100505715 belongs to is a member of the ZNF2 gene family, which is known for the regulation of cell growth, differentiation, and survival. ZNF2 is a transcription factor that has been implicated in the development and maintenance of various diseases, including cancer, neurodegenerative diseases, and developmental disorders. The ZNF2 gene has four splice variants, each of which produces a unique isoform of the protein.
LOC100505715 is a splicing variant of the ZNF2 gene that is predominantly expressed in the brain and other tissues of the body. It is characterized by the presence of a unique 24 amino acid residue at its C-terminus. This residue is known as an N-terminal hypervariable region (HVR), which is a region of the protein that can vary in length and sequence among different isoforms.
The N-terminal HVR of LOC100505715 is composed of a unique sequence that is not found in any of the other splice variants of ZNF2. This sequence is highly conserved across different isoforms of ZNF2, which suggests that it is an important region of the protein that contributes to its overall stability and function.
In addition to its unique N-terminal HVR, LOC100505715 is also characterized by the presence of a unique C-terminal region that is not found in any of the other splice variants of ZNF2. This region is composed of a unique sequence that is highly conserved across different isoforms of ZNF2 and is not known to be involved in the function of the protein.
The expression of LOC100505715 is regulated by various factors, including cytokines, chemokines, and growth factors. For example, it has been shown to be regulated by factors such as PDGF, TGF-β, and NF-kappa-B. These factors can induce the formation of LRR-containing aggregates, which have been shown to be both beneficial and detrimental to various cellular processes.
The aggregation of LRR-containing proteins has been shown to play a role in a variety of cellular processes, including cell survival, migration, and invasion. In addition, the formation of LRR-containing aggregates has also been implicated in the development of various diseases, including cancer, neurodegenerative diseases, and developmental disorders.
The unique N-terminal HVR and C-terminal region of LOC100505715 make it an attractive target for drug development. By modifying the N-terminal or C-terminal region of this protein, it is possible to alter its function and activity. This could provide new insights into the regulation of LRR-containing proteins and the potential implications of these proteins for various diseases.
In conclusion, LOC100505715 is a unique and promising protein that is characterized by the presence of a unique N-terminal HVR and C-terminal region. Its unique expression and regulation by various factors make it an attractive target for drug development. Further studies are needed to fully understand the function of LOC100505715 and its potential implications for various diseases.
Protein Name: Uncharacterized LOC100505715
The "LOC100505715 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC100505715 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC100505716 | LOC100505841 | LOC100505912 | LOC100505915 | LOC100505978 | LOC100506023 | LOC100506071 | LOC100506076 | LOC100506124 | LOC100506207 | LOC100506236 | LOC100506274 | LOC100506281 | LOC100506379 | LOC100506403 | LOC100506422 | LOC100506444 | LOC100506446 | LOC100506472 | LOC100506474 | LOC100506499 | LOC100506514 | LOC100506532 | LOC100506606 | LOC100506634 | LOC100506639 | LOC100506667 | LOC100506730 | LOC100506974 | LOC100507002 | LOC100507006 | LOC100507053 | LOC100507054 | LOC100507156 | LOC100507165 | LOC100507221 | LOC100507250 | LOC100507336 | LOC100507346 | LOC100507351 | LOC100507389 | LOC100507412 | LOC100507424 | LOC100507443 | LOC100507513 | LOC100507520 | LOC100507547 | LOC100507577 | LOC100507656 | LOC100509646 | LOC100533709 | LOC100630923 | LOC100652743 | LOC100652768 | LOC100652833 | LOC100652999 | LOC100653061 | LOC100996385 | LOC100996412 | LOC100996583 | LOC100996637 | LOC100996643 | LOC100996664 | LOC100996770 | LOC101060017 | LOC101060106 | LOC101060179 | LOC101060400 | LOC101060445 | LOC101060524 | LOC101060632 | LOC101448202 | LOC101593348 | LOC101926887 | LOC101926948 | LOC101926953 | LOC101926959 | LOC101926969 | LOC101927002 | LOC101927020 | LOC101927025 | LOC101927026 | LOC101927040 | LOC101927053 | LOC101927060 | LOC101927066 | LOC101927082 | LOC101927108 | LOC101927143 | LOC101927164 | LOC101927166 | LOC101927169 | LOC101927179 | LOC101927188 | LOC101927199 | LOC101927216 | LOC101927243 | LOC101927245 | LOC101927253 | LOC101927263
